RxDoctor Payments Data

Shaum Sridharan

Otolaryngology · Washington, DCNPI 1114192184

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $6,301 of the $8,379 with a category attached, or 75.2%. Medical Device Business Services, Inc. accounts for 81.2% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $6,459 and has fallen 95.1% since, to $319 in 2025.

$8,379in general payments, 2019–2025

Across 27 payments — averaging $310.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medical Device Business Services, Inc.$7K
  • Integra Lifesciences Corporation$411
  • Axogen$343
  • Baxter Healthcare$301
  • Johnson & Johnson$257
  • Stryker$159
  • plus $105 from 1 others

What the payments were for

  • Consulting fees$6,30175%
  • Travel & lodging$911%
  • Food & beverage$1,98824%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,379 in reported general payments places this provider in the 85th percentile of 41 otolaryngology providers in District of Columbia.

See all otolaryngology providers in District of Columbia

Medicare billing

Part B allowed, 2024
$100,342
Medicare patients
143
Services billed
373

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Pentoxifylline11$249
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav24$215
Famotidine19$163

Paid to pharmacies, not to this prescriber.

Other otolaryngology in Washington

See the full list for District of Columbia

Where these figures come from

Is this you, or does something look wrong? →